Document is current
Any future updates will be listed below
-
Authors
Aguilar, Rhiannon R. https://orcid.org/0000-0001-5723-608X
Khan, Laiba F. https://orcid.org/0009-0000-5427-0653
Cummins, Christopher K.
Arslanovic, Nina
Grauer, Thea
Birmingham, Kaylah
Kasliwal, Kritika
Posnikoff, Spike D. L.
Chakraborty, Ujani
Hickman, Allison R. https://orcid.org/0009-0007-7901-6687
Watson, Rachel
Ezell, Ryan J.
Hunt, Sabrina R.
Mukhsinova, Laylo https://orcid.org/0009-0008-7689-3497
Willis, Hannah E. https://orcid.org/0009-0001-5996-2322
Cowles, Martis W.
Garner, Richard
Shim, Abraham https://orcid.org/0000-0001-5351-0774
Gutierrez, J. Ignacio https://orcid.org/0000-0002-9017-8384
Venters, Bryan J. https://orcid.org/0000-0002-4607-0587
Marunde, Matthew R.
Strahl, Brian D. https://orcid.org/0000-0002-4947-6259
Keogh, Michael-Christopher https://orcid.org/0000-0002-2219-8623
Tyler, Jessica K. https://orcid.org/0000-0001-9765-1659
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (R35 GM139816)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01 CA95641)
- License Information
-
More Information
Article History
Received: 18 July 2023
Accepted: 25 August 2025
First Online: 29 September 2025
Competing interests
: EpiCypher is a commercial developer and supplier of reagents (e.g., fully defined semi-synthetic nucleosomes (dNucs) and SNAP-CUTANA® K-MetStat spike-ins) and platforms (e.g., Captify™ and CUTANA™ CUT&RUN) used in this study. LFK, ARH, RW, SRH, LM, MWC, MRM and MCK are currently employed by (and own shares in) EpiCypher. RJE and HEW were previously employed by (and own shares in) EpiCypher. MWC, BDS and MCK are board members of EpiCypher. The remaining authors declare no competing interests.
